Apolipoprotein E and Alzheimer's disease

被引:41
|
作者
Troutwine, Benjamin R. [1 ,2 ]
Hamid, Laylan [2 ]
Lysaker, Colton R. [2 ,3 ]
Strope, Taylor A. [2 ,3 ]
Wilkins, Heather M. [1 ,2 ,3 ]
机构
[1] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA
[2] Univ Kansas, Alzheimers Dis Ctr, Kansas City, KS 66160 USA
[3] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA
基金
美国国家卫生研究院;
关键词
Apolipoprotein E; Alzheimer's disease; Mitochondria; Neuroinflammation; Amyloid beta; Tau; AMYLOID-BETA-PEPTIDE; ISOFORM-DEPENDENT MANNER; APOE EPSILON-4 ALLELE; E POLYMORPHISM; E GENOTYPE; CYTOCHROME-OXIDASE; NEURITE OUTGROWTH; MOUSE MODEL; LIPOPROTEIN RECEPTORS; POSTERIOR CINGULATE;
D O I
10.1016/j.apsb.2021.10.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Genetic variation in apolipoprotein E (APOE) influences Alzheimer's disease (AD) risk. APOE epsilon 4 alleles are the strongest genetic risk factor for late onset sporadic AD. The AD risk is dose dependent, as those carrying one APOE epsilon 4 allele have a 2-3-fold increased risk, while those carrying two epsilon 4 alleles have a 10-15-fold increased risk. Individuals carrying APOE epsilon 2 alleles have lower AD risk and those carrying APOE epsilon 3 alleles have neutral risk. APOE is a lipoprotein which functions in lipid transport, metabolism, and inflammatory modulation. Isoform specific effects of APOE within the brain include alterations to A beta, tau, neuroinflammation, and metabolism. Here we review the association of APOE with AD, the APOE isoform specific effects within brain and periphery, and potential therapeutics. (c) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:496 / 510
页数:15
相关论文
共 50 条
  • [31] Targeting apolipoprotein E for treating Alzheimer's disease
    Bales, Kelly R.
    Paul, Steven M.
    [J]. NEUROSCIENCE LETTERS, 2019, 709
  • [32] Apolipoprotein E and neurofibrillary tangles in Alzheimer's disease
    Ohm, TG
    Scharnagl, H
    Marz, W
    [J]. BASIC AND CLINICAL SCIENCE OF MENTAL AND ADDICTIVE DISORDERS, 1997, (167): : 119 - 122
  • [33] The vascular contribution of apolipoprotein E to Alzheimer's disease
    Chen, Feng
    Zhao, Jing
    Meng, Fanxia
    He, Fangping
    Ni, Jie
    Fu, Yuan
    [J]. BRAIN, 2024, 147 (09) : 2946 - 2965
  • [34] Advances in research of apolipoprotein E and Alzheimer's disease
    Liu Qian
    Wu Weihui
    Li Renwang
    Zheng Yizhe
    Zhao Yufen
    Li Yanmei
    [J]. PROGRESS IN CHEMISTRY, 2007, 19 (12) : 2006 - 2011
  • [35] Human apolipoprotein E: The Alzheimer's disease connection
    Weisgraber, KH
    Mahley, RW
    [J]. FASEB JOURNAL, 1996, 10 (13): : 1485 - 1494
  • [36] Clinical correlates of apolipoprotein E in Alzheimer's disease
    Frisoni, GB
    Bianchetti, A
    Govoni, S
    Trabucchi, M
    [J]. ANNALS OF NEUROLOGY, 1996, 40 (04) : 688 - 689
  • [37] The relevance of apolipoprotein E polymorphism to alzheimer's disease
    Narayanan S.
    [J]. Indian Journal of Clinical Biochemistry, 1999, 14 (1) : 40 - 48
  • [38] Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease
    Kamboh, MI
    DeKosky, ST
    [J]. ANNALS OF NEUROLOGY, 1995, 38 (06) : 967 - 969
  • [39] Alzheimer's disease - Apolipoprotein E and cognitive performance
    Raber, J
    Wong, D
    Yu, GQ
    Buttini, M
    Mahley, RW
    Pitas, RE
    Mucke, L
    [J]. NATURE, 2000, 404 (6776) : 352 - 354
  • [40] Apolipoprotein E and Alzheimer disease
    Lahoz, C
    Ordovas, JM
    [J]. REVISTA CLINICA ESPANOLA, 1997, 197 (02): : 73 - 74